• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>RSC Advances >In vitro combinations of inert phenolato Ti(iv) complexes with clinically employed anticancer chemotherapy: synergy with oxaliplatin on colon cells
【24h】

In vitro combinations of inert phenolato Ti(iv) complexes with clinically employed anticancer chemotherapy: synergy with oxaliplatin on colon cells

机译：惰性酚基钛（iv）配合物与临床采用的抗癌化学疗法的体外组合：与奥沙利铂对结肠细胞的协同作用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Advanced anticancer phenolato titanium( IV ) complexes were combined with known chemotherapeutic anticancer drugs applied in the clinic and were analyzed in vitro on cell lines most sensitive to the Ti( IV ) complex and relevant to the clinical application of the known drugs. Combination of the Ti( IV ) complex with cisplatin on ovarian cells showed mostly an additive behavior, also on a line resistant to cisplatin. Combination of the Ti( IV ) complex with fluorouracil on colon cells gave near additive behavior, and that with oxaliplatin gave a synergistic behavior at a wide range of Ti?:?Pt ratios, but only when the drugs were administered together. Increasing the time intervals between the administration of Ti and of Pt turned the behavior to antagonistic, suggesting some deactivation of Pt by the Ti agent. For combinations where the drugs were applied together, the behavior depended on the effect level, and higher effects gave greater synergism, implying that technical aspects such as solubility are influential. Nevertheless, more complex patterns recorded for combinations where the drugs had been applied separately suggested multiple mechanisms with different concentration dependence. Overall the results point to high medicinal potential for the tested compounds for anticancer combination treatments.
机译：将先进的抗癌酚酚钛（IV）复合物与临床上使用的已知化学治疗抗癌药物组合，并在对Ti（IV）络合物最敏感且与已知药物的临床应用相关的细胞系上进行体外分析。 Ti（IV）复合物与顺铂在卵巢细胞上的结合主要表现出累加行为，也表现在对顺铂耐药的品系上。 Ti（IV）配合物与氟尿嘧啶在结肠细胞上的结合具有相近的加性行为，而与奥沙利铂的结合在宽范围的Ti2：？Pt比下具有协同作用，但仅当药物一起给药时才如此。增加Ti和Pt施用之间的时间间隔会使行为变成拮抗性，表明Ti试剂会导致Pt失活。对于药物一起使用的组合，其行为取决于效果水平，更高的效果可产生更大的协同作用，这意味着诸如溶解度之类的技术方面具有影响力。然而，在单独使用药物的组合中记录的更复杂的模式提示具有不同浓度依赖性的多种机制。总体而言，结果表明该化合物可用于抗癌联合治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号